← Leaderboards
Stephen Fiacco
Evorx Technologies, Inc.
$1,551,238
Attributed
$2,552,738
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–18$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,552,738 · 3
By mechanism
R44$2,003,000 · 1
N43$549,738 · 2
Top collaborators
- Steven W Millward3 shared
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmLeadTumorLiverTechnologyImageResistanceToxic EffectUptakeAntibodiesPeptidesPeptide HydrolasesIn VivoBlood CirculationBiopsyPet/Ct ScanPenetrationPhysiciansMalignant NeoplasmsMolecular ImagingCancer CenterMolecularNoiseBreast Cancer Treatment
Grant awards (5)
Development of SUPR peptides as PET Imaging Agents for Her2+ Breast Cancer$3,090
R44 · FY2018 · CA · contact PI
Development of SUPR peptides as PET Imaging Agents for Her2+ Breast Cancer$1,144,342
R44 · FY2017 · CA · contact PI
Development of SUPR peptides as PET Imaging Agents for Her2+ Breast Cancer$855,568
R44 · FY2016 · CA · contact PI
SUPR Peptides for Targeted Radionuclide Delivery$299,990
N43 · FY2015 · CA · contact PI
TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE$249,748
N43 · FY2013 · CA · contact PI